Scailyte
Scailyte develops an AI platform called ScaiVision that utilizes supervised representation learning and generative models to analyze single-cell and spatial omics data. The company focuses on autoimmune diseases, specifically Inflammatory Bowel Disease, to identify molecular patterns and patient endotypes for drug target discovery and clinical trial stratification. Their services are designed for pharmaceutical partners to de-risk assets, discover novel targets, and develop precision companion diagnostics.
AI
Healthcare
Biotechnology
Diagnostics
Pharmaceuticals
Funding summary
- Total raised
- €21.7M
- Funding rounds
- 6
- Exit
- acquisition
- Exit value
- —
Investors in Scailyte
Investors on record for Scailyte. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Scailyte?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors